Patent valuation services produce a number. Whether that number is worth anything depends on whether you can see how it was reached.
Three approaches underlie all of them — cost, market and income — and income dominates for patents.
The inputs are judgements, not measurements. Royalty rate, revenue base, discount rate, useful life.
A report that does not state those cannot be checked by anyone, and that is the single most useful test to apply before commissioning one.
What you are commissioning
| Output | Purpose |
|---|---|
| An indication | Internal decision |
| A full report | Transaction or financing |
| An expert report | Litigation |
| A portfolio review | Strategy |
Price and rigour scale with purpose. Ask what standard the report is prepared to before comparing quotes.
The test to apply
Can you see the assumptions? If not, the number cannot be checked by you or by anyone you show it to.
The three approaches
| Approach | Asks | Fit for patents |
|---|---|---|
| Income | What future benefit does it produce? | Dominant |
| Market | What have comparable assets sold for? | Where comparables exist |
| Cost | What did it take to create or replace? | Weak |
Cost is weak because prosecution spend says nothing about coverage. Money spent on office actions reflects how hard the examiner was, not what the claims reach.
Market suffers from thin data. Most patent transactions are private and disclosed deals frequently bundle assets.
Cost approach, and why it misleads
| Input | What it reflects |
|---|---|
| Prosecution spend | How hard the examiner was |
| Number of office actions | Difficulty, not scope |
| Drafting cost | Complexity of description |
| None of it | What the claims cover |
Income methods
| Method | Detail |
|---|---|
| Relief from royalty | What you would pay to license it if you did not own it |
| Excess earnings | Earnings above a business without it |
| Incremental cash flow | The difference the asset makes |
| Cost savings | Where it reduces expense rather than raising revenue |
Relief from royalty is the most portable and it reduces the whole question to two numbers — a rate and a base.
Both are contested. The same rate applied to a component or a finished product can differ by more than an order of magnitude. See patent royalty rates.
Before commissioning anything
| Free check | Time |
|---|---|
| In force? | 3 min |
| Who owns it? | 5 min |
| Remaining term from the earliest parent | 5 min |
| Any encumbrances recorded | 5 min |
A valuation of a lapsed patent is a wasted fee.
Who provides valuations
| Provider | Typical use |
|---|---|
| Specialist IP valuation firms | Transactions, financing |
| Accounting firms | Tax and reporting |
| Some brokers | Pre-sale indication |
| Expert witnesses | Litigation |
What a usable report contains
| Element | Why |
|---|---|
| Method used, and why | Different methods suit different assets |
| Royalty rate assumed, and its basis | The core input |
| Revenue base, and why that base | Moves the answer most |
| Discount rate | Compounds over the horizon |
| Useful life | Remaining term, adjusted |
| Maintenance costs subtracted | A buyer inherits them |
| Stated limitations | What could not be verified |
| Status and ownership verified | Or explicitly assumed |
"Stated limitations" is the mark of a serious report. One presenting a figure without saying what it could not confirm is presenting confidence rather than analysis.
Where the variance comes from
| Input | Effect of a small change |
|---|---|
| Royalty rate | Proportional |
| Revenue base | Proportional — and contested hardest |
| Discount rate | Compounds over the horizon |
| Useful life | Truncates or extends everything |
| Probability adjustments | Multiplies through |
Two defensible valuations of the same patent can differ enormously. That is not a failure of the discipline; it is what happens when four judgements multiply.
Which is why stated assumptions matter more than the headline figure.
What actually drives value
| Driver | Weight |
|---|---|
| Claims read on products in the market | Highest |
| Documented evidence of that | Very high |
| Remaining term | High |
| Clean recorded ownership | Blocking if absent |
| Family depth and jurisdictions | High |
| Validity robustness | High |
| Prosecution spend | Low |
| Patent count | Low |
A documented claim chart against a shipping product is the largest single factor. A patent with one is a different asset from a patent without one. See claim chart example.
Ownership defects are blocking rather than discounting. Buyers do not negotiate around a broken chain; they walk.
Foreign members add cost, not just value
| US only | Multi-jurisdiction | |
|---|---|---|
| Renewal events | 3 per patent | Annual per country |
| Carrying cost | Bounded | Escalating |
| Diligence | One chain | Per jurisdiction |
Subtract what a buyer inherits
| Fee | Due after grant | Large | Small | Micro |
|---|---|---|---|---|
| First | 3.5 years | $2,150 | $860 | $430 |
| Second | 7.5 years | $4,040 | $1,616 | $808 |
| Third | 11.5 years | $8,280 | $3,312 | $1,656 |
| Total | $14,470 | $5,788 | $2,894 |
Foreign annuities add more, annually and escalating. A valuation ignoring the carrying cost overstates what anyone would pay.
Ranges beat point estimates
| Output | Assessment |
|---|---|
| A single figure | Overstates precision |
| A range with drivers | Honest |
| Scenarios | Better still |
| Sensitivity to base and rate | Most informative |
Remaining term drives decay
| Remaining term | Effect |
|---|---|
| 12+ years | Full income horizon |
| 8–11 years | Strong |
| 5–7 years | Meaningfully reduced |
| Under 3 years | Most buyers decline outright |
| Expired | Zero |
The decay is not linear. Below roughly three years many buyers will not transact regardless of the claims, because assertion and licensing both take time.
Calculate term from the earliest parent, never the filing date shown. Continuation chains routinely make a patent shorter than it looks.
Portfolio versus single asset
| Single patent | Portfolio | |
|---|---|---|
| Method | Direct income or market | Aggregate, with segmentation |
| Diligence burden | Low | Per family |
| Blended figure | Not applicable | Hides where value sits |
| Reporting | One figure | Components, always |
A single portfolio number hides which assets carry the value. Ask for the components, because in most portfolios a small number of families account for nearly all of it.
What data exists
| Available | Not available |
|---|---|
| Academic value estimates | Comprehensive transaction prices |
| Some disclosed licence terms | Most licence terms — private |
| Litigation damages awards | Settlement amounts — usually confidential |
| Brokered-deal reported pricing | A complete market record |
| Maintenance fee behaviour | Reasons for individual decisions |
No public dataset contains patent sale prices at scale. Academic datasets such as KPSS provide value estimates derived from stock-market reactions at grant — modelled estimates rather than records of sales, since no transaction occurs and no price is paid.
Treating those as transaction prices is a common misreading, and it is worth asking any provider how they describe their sources. See intellectual property valuation.
Red flags in a valuation
| Signal | Meaning |
|---|---|
| No stated assumptions | Cannot be checked |
| "Proprietary method" | Cannot be interrogated |
| A single figure, no range | Overstates precision |
| Status and ownership assumed | May be valuing a dead patent |
| Cost approach used for a patent | Wrong method |
| Sources described as transaction prices | Frequently value estimates |
A single number with no range overstates precision. The inputs are judgements, so the honest output is a range with the drivers identified.
Questions before commissioning
| Ask | Weak answer |
|---|---|
| What method, and why that one? | "Proprietary" |
| Will you state the assumptions? | Evasion |
| Do you verify status and ownership? | "We use what you give us" |
| What data sources, and how described? | Overstated |
| What standard is the report prepared to? | None stated |
| Who signs it, and their qualifications? | Unclear |
| What are the limitations? | "None" |
"Proprietary method" is the answer to be most cautious about. A valuation you cannot interrogate is a number you cannot defend in a negotiation, to a lender, or in a proceeding.
Purpose shapes method
| Purpose | Emphasis |
|---|---|
| Sale or purchase | Market and income |
| Licensing negotiation | Relief from royalty |
| Financing | Realisable value, conservative |
| Litigation damages | Statutory framework, not general valuation |
| Tax and accounting | Standard-driven |
| Insolvency | Liquidation basis |
Damages are not a valuation exercise. They follow the statutory framework — reasonable royalty floor, lost profits above it, apportionment — which is a different analysis. See patent infringement damages.
What you can check yourself, free
| Check | Source | Time |
|---|---|---|
| In force? | USPTO Patent Center | 3 min |
| Who owns it? | USPTO Assignment Search | 5 min |
| Remaining term, from the earliest parent | Front page + family | 5 min |
| Encumbrances recorded | Assignment Search | 5 min |
| Does anyone practise the claims? | Product docs, competitor filings | Hours |
| Ipiry Patent Survival Curve v1.0 | Rate |
|---|---|
| Survive the 3.5-year fee (2022 cohort) | 85.8% |
| Survive the 7.5-year fee (2018 cohort) | 64.6% |
| Reach full term (2014 cohort) | 41.4% |
| Abandoned before full term | 58.6% |
Computed from 27,273,654 USPTO maintenance fee records covering 8,262,336 US utility patents — see the patent survival curve.
Run these before commissioning anything. A valuation of a lapsed patent is a wasted fee, and checking takes minutes.
Patent valuation services: the checklist
- Prefer income methods. Cost tells you least about a patent.
- Demand stated assumptions — rate, base, discount rate, useful life.
- Treat "proprietary method" as a warning, not a reassurance.
- Confirm they verify status and ownership, or do it yourself first.
- Check the revenue base carefully. It moves the answer most.
- Subtract maintenance fees and annuities from any figure.
- Weight documented evidence of use above every other factor.
- Calculate remaining term from the earliest parent.
- Ask how sources are described. Value estimates are not sale prices.
- Match the method to the purpose. Damages follow a statutory framework instead.